Efficacy and safety of fuzoparib combined with anlotinib in extensive stage small cell lung cancer after first-line platinum-based chemotherapy: A multi-center, single-arm prospective phase II clinical study (STAMP study)
Số trang: 11
Loại file: pdf
Dung lượng: 1.05 MB
Lượt xem: 9
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Small-cell lung cancer (SCLC) is a highly aggressive and lethal malignancy that accounts for 10–15% of lung cancers, and it is generally divided into limited and extensive stage. The standard of care for patients with newly diagnosed extensive-stage SCLC (ES-SCLC) is still platinum-based chemotherapy and as maintenance therapy scheme.
Nội dung trích xuất từ tài liệu:
Efficacy and safety of fuzoparib combined with anlotinib in extensive stage small cell lung cancer after first-line platinum-based chemotherapy: A multi-center, single-arm prospective phase II clinical study (STAMP study)
Nội dung trích xuất từ tài liệu:
Efficacy and safety of fuzoparib combined with anlotinib in extensive stage small cell lung cancer after first-line platinum-based chemotherapy: A multi-center, single-arm prospective phase II clinical study (STAMP study)
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Small cell lung cancer Lung cancers Lethal malignancy Still platinum-based chemotherapy Maintenance therapy schemeTài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 171 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 142 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 120 0 0 -
12 trang 93 0 0
-
19 trang 74 0 0
-
17 trang 64 0 0
-
9 trang 43 0 0
-
12 trang 38 0 0
-
13 trang 38 0 0